

# Fatemeh Akhlaghi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3188400/publications.pdf>

Version: 2024-02-01

31  
papers

1,133  
citations

623734  
14  
h-index

434195  
31  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1797  
citing authors

#	ARTICLE	IF	CITATIONS
1	A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. <i>Molecular Psychiatry</i> , 2021, 26, 545-555.	7.9	21
2	Treprostinil, a prostacyclin analog, ameliorates renal ischemiaâ€“reperfusion injury: preclinical studies in a rat model of acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 257-266.	0.7	9
3	A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers. <i>Clinical Pharmacokinetics</i> , 2021, 60, 471-484.	3.5	7
4	Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 464-476.	2.1	11
5	Effect of oral alcohol administration on plasma cytokine concentrations in heavy drinking individuals. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108771.	3.2	8
6	Treprostinil reduces mitochondrial injury during rat renal ischemia-reperfusion injury. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111912.	5.6	8
7	Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). <i>PLoS ONE</i> , 2021, 16, e0251665.	2.5	7
8	Synthesis of PF-6870961, a major hydroxy metabolite of the novel ghrelin receptor inverse agonist PF-5190457. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 50, 116465.	3.0	2
9	Development of a Physiologically Based Pharmacokinetic Model for Prediction of Ethanol Concentration-Time Profile in Different Organs. <i>Alcohol and Alcoholism</i> , 2021, 56, 401-414.	1.6	1
10	The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. <i>Molecular Psychiatry</i> , 2020, 25, 461-475.	7.9	90
11	Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers. <i>Neuropharmacology</i> , 2020, 170, 107788.	4.1	19
12	Perfluorooctanesulfonic acid (PFOS) administration shifts the hepatic proteome and augments dietary outcomes related to hepatic steatosis in mice. <i>Toxicology and Applied Pharmacology</i> , 2020, 408, 115250.	2.8	31
13	Short-term treatment with dabigatran alters protein expression patterns in a late-stage tau-based Alzheimer's disease mouse model. <i>Biochemistry and Biophysics Reports</i> , 2020, 24, 100862.	1.3	4
14	Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies. <i>Brain Research</i> , 2020, 1740, 146851.	2.2	13
15	Most Influential Physicochemical and In Vitro Assay Descriptors for Hepatotoxicity and Nephrotoxicity Prediction. <i>Chemical Research in Toxicology</i> , 2020, 33, 1780-1790.	3.3	3
16	Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS/MS in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1130-1131, 121820.	2.3	4
17	Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach. <i>Drug Metabolism and Disposition</i> , 2019, 47, 874-882.	3.3	11
18	Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1281-1294.	3.5	98

#	ARTICLE	IF	CITATIONS
19	Tacrolimus Concentration in Saliva of Kidney Transplant Recipients: Factors Influencing the Relationship with Whole Blood Concentrations. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1199-1210.	3.5	12
20	Dysregulation of $11\beta$ -4-3-oxosteroid $5\alpha$ -reductase in diabetic patients: Implications and mechanisms. <i>Molecular and Cellular Endocrinology</i> , 2018, 470, 127-141.	3.2	18
21	Identifying and Characterizing Subpopulations of Heavy Alcohol Drinkers Via a Sucrose Preference Test: A Sweet Road to a Better Phenotypic Characterization?. <i>Alcohol and Alcoholism</i> , 2018, 53, 560-569.	1.6	10
22	Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver. <i>Molecular Pharmaceutics</i> , 2018, 15, 2621-2632.	4.6	76
23	Pharmacological manipulation of the ghrelin system and alcohol hangover symptoms in heavy drinking individuals: Is there a link?. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 172, 39-49.	2.9	19
24	Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. <i>Drug Metabolism Reviews</i> , 2017, 49, 197-211.	3.6	414
25	Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS. <i>Journal of Proteome Research</i> , 2017, 16, 4134-4143.	3.7	34
26	Characterization of Byproducts from Chemical Syntheses of Oligonucleotides Containing 1-Methyladenine and 3-Methylcytosine. <i>ACS Omega</i> , 2017, 2, 8205-8212.	3.5	9
27	Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2017, 56, 561-571.	3.5	17
28	Pharmacokinetics of Mycophenolic Acid and Metabolites in Diabetic Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 95-101.	2.0	29
29	Association Between Cyclosporine Concentrations at 2 Hours Post-dose and Clinical Outcomes in De Novo Lung Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 2120-2128.	0.6	17
30	Risk factors for the development and progression of dyslipidemia after heart transplantation. <i>Transplantation</i> , 2002, 73, 1258-1264.	1.0	26
31	Distribution of Cyclosporin in Organ Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2002, 41, 615-637.	3.5	105